Zevra Therapeutics, Inc.
General ticker "ZVRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $544.6M (TTM average)
Zevra Therapeutics, Inc. follows the US Stock Market performance with the rate: 21.5%.
Estimated limits based on current volatility of 2.5%: low 13.84$, high 14.45$
Factors to consider:
- Total employees count: 61 (+3.4%) as of 2025
- Top business risk factors: Limited commercial capabilities, Market acceptance, Economic downturns and volatility, Adverse safety events, Regulatory and compliance
- Current price 16.1% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.76$, 12.04$]
- 2026-12-31 to 2027-12-31 estimated range: [5.49$, 11.58$]
Financial Metrics affecting the ZVRA estimates:
- Positive: with PPE of 3.7 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 42.57 < Shareholder equity ratio, % of 54.32 <= 64.23
- Positive: Return on assets ratio (scaled to [-100,100]) of 22.62 > 6.02
- Negative: negative Industry operating income (median)
- Positive: Investing cash flow per share per price, % of 3.82 > -0.60
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term ZVRA quotes
Long-term ZVRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $27.46MM | $23.61MM | $106.47MM |
| Operating Expenses | $77.06MM | $110.61MM | $169.41MM |
| Operating Income | $-49.60MM | $-87.00MM | $-62.94MM |
| Non-Operating Income | $3.56MM | $-3.14MM | $149.62MM |
| Interest Expense | $1.50MM | $7.35MM | $7.98MM |
| R&D Expense | $39.81MM | $42.09MM | $12.74MM |
| Income(Loss) | $-46.05MM | $-90.14MM | $86.68MM |
| Taxes | $0.00MM | $15.37MM | $3.45MM |
| Net Income(Loss)* | $-46.05MM | $-105.51MM | $83.23MM |
| Stockholders Equity | $61.86MM | $39.67MM | $154.66MM |
| Inventory | $24.08MM | $1.97MM | $1.74MM |
| Assets | $172.33MM | $178.13MM | $284.73MM |
| Operating Cash Flow | $-33.53MM | $-69.67MM | $-1.60MM |
| Capital expenditure | $0.30MM | $0.00MM | $0.83MM |
| Investing Cash Flow | $-17.39MM | $-22.16MM | $18.13MM |
| Financing Cash Flow | $28.46MM | $82.11MM | $12.06MM |
| Earnings Per Share** | $-1.30 | $-2.28 | $1.50 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.